By upgrading from ÄKTAexplorer to ÄKTA avant chromatography system, you can improve productivity in process development. Depending on your application and how the system is operated, different ways to improve your productivity will have varying impact. Here we show 10 ways to boost your productivity.
The growing public awareness of a potential pandemic requiring rapid treatment of millions of healthy individuals has spurred renewed interest in vaccines. Vaccine development timelines vary from being only a fraction of other biotherapeutics to decades of research and efforts to find an effective vaccine. Vaccination campaigns mean that often very large quantities need to be manufactured, maintained, and distributed.
Biotech Millennium found that by clearly defining workflows and implementing a highly configurable notebook, it could move its entire discovery organization to a single ELN system.
If current manufacturing practices are followed to handle small batches of API on industrial size machines, it results in handling difficulties and lower product yield.
ReadyToProcess™ columns are prepacked, prequalified, and presanitized process chromatography columns suited for purification of biopharmaceuticals (e.g., proteins, vaccines, plasmids, and viruses) for clinical phase I and II studies. ReadyToProcess columns are available with several media at different volumes (1, 2.5, 10, and 20 L).
The PDA Journal of Pharmaceutical Science and Technology, have taught us that using materials not intended for use with pharmaceuticals was not the best choice. The industry is now evolving toward developing single-use films better suited to fit the needs of biomanufacturing, specifically, end users that have communicated a need for improved film performance with reliable supply, which requires transparency along the entire supply chain.
Manual buffer preparation for high-throughput process development (HTPD) requires a lot of effort as the number of different buffer conditions is large.
Zydis® fast dissolve formulation for Zelapar® (Selegiline anti-Parkinson’s compound) had a positive impact on the patient compliance as compared to the Selegiline traditional tablets.
The pilot scale synthesis instruments from GE Healthcare, ÄKTA oligopilot 10 and ÄKTA oligopilot 100 have been upgraded in regards to hardware, software, and synthesis methods. As a result of the upgrade, ÄKTA oligopilot plus 10 has become a highly efficient system for 1-µmol scale synthesis of DNA oligonucleotides
In the shift to single-use technology, there is both an opportunity and an obligation to understand the sustainability impacts of this development.
|
|
|
|
|
|
|
|
|